Thermo Fisher Scientific Expands PPD Laboratory Services Network With New Bioanalytical Facility In Sweden

Endpoints NewsRegeneron reaches $125M Parabilis deal for hard-to-catch drug targets

FierceBiotechBioMarin’s $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal

FierceBiotechAfter rare disease flop, cash-strapped Quince finds salvation in reverse merger

BioWorldBiggest gainers and losers for May 11-15, 2026

Endpoints NewsDesign Therapeutics' Friedreich's ataxia data; Vincentage's obesity results from China

BioPharma DiveHøeg fired in latest FDA shakeup; 20 people die after taking Amgen drug

Endpoints NewsMerck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule

Endpoints NewsThe Supreme Court won't take up drugmakers' IRA cases

FierceBiotechNominations now open for Fierce Biotech's 2026 Fierce 15

FierceBiotechRegeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy

FierceBiotechVincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators

PharmaVoiceRace intensifies to lead next wave of obesity drugs as trial results loom